| Minimally Invasive Imagery With Indocyanine Green (NCT02621268) | University of Pennsylvania | 2014-11-01 |
| Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid Tumours (NCT02314884) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2014-11-01 |
| The Orkdal Model. Collaboration Between Specialist and Community Care Within Palliative Cancer Care (NCT02170168) | St. Olavs Hospital | 2014-11-01 |
| Concordance Between ctDNA Assay and FoundationOne (NCT02620527) | Foundation Medicine | 2014-11-01 |
| GREAT - Good Response With Appropriate Treatment (NCT02293785) | Mario Negri Institute for Pharmacological Research | 2014-11-01 |
| Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (NCT02223052) | Celgene | 2014-10-27 |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors (NCT02222922) | Pfizer | 2014-10-17 |
| Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors (NCT02211755) | National Cancer Institute (NCI) | 2014-10-06 |
| Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer (NCT02491580) | Uppsala University | 2014-10-01 |
| Beyond TME Origins (NCT02292641) | Imperial College London | 2014-09-25 |
| A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02219724) | Genentech, Inc. | 2014-08-12 |
| A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (NCT02081495) | Janssen Research & Development, LLC | 2014-08-01 |
| A Study Of PF-06664178 In Patients With Advanced Solid Tumors (NCT02122146) | Pfizer | 2014-08-01 |
| A Study of LY3164530 in Participants With Cancer (NCT02221882) | Eli Lilly and Company | 2014-08-01 |
| A Psychosocial Intervention Plus Early Palliative Care in the Reduction of Depression of Advanced Cancer Patients (NCT02133274) | Barretos Cancer Hospital | 2014-08-01 |
| Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being (NCT02899117) | Connecticut Children's Medical Center | 2014-08-01 |
| Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer (NCT02215837) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2014-08-01 |
| A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies (NCT02158858) | Constellation Pharmaceuticals | 2014-07-16 |
| Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting (NCT02203253) | China Medical University, China | 2014-07-01 |
| Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer (NCT02202928) | Shenzhen Hornetcorn Bio-technology Company, LTD | 2014-07-01 |
| First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients (NCT02194426) | Molecular Partners AG | 2014-07-01 |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (NCT02155634) | Celgene | 2014-07-01 |
| Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer (NCT02168777) | Bayer | 2014-06-23 |
| Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours (NCT02145741) | Boehringer Ingelheim | 2014-06-11 |
| Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors (NCT02168725) | Traws Pharma, Inc. | 2014-06-01 |
| Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis (NCT01999179) | Medical College of Wisconsin | 2014-06-01 |
| Dose-escalation Study of Lupartumab Amadotin (BAY1129980) (NCT02134197) | Bayer | 2014-05-22 |
| Japanese BAY1000394 Monotherapy Phase I Study (NCT02047890) | Bayer | 2014-05-19 |
| BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer (NCT02123823) | Boehringer Ingelheim | 2014-05-15 |
| Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors (NCT02077933) | Novartis Pharmaceuticals | 2014-05-14 |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies (NCT01943851) | GlaxoSmithKline | 2014-05-14 |
| iKnife REIMS Project (NCT04067388) | Imperial College London | 2014-05-01 |
| Genetic Exploration of the Molecular Basis of Malignancy in Adults (NCT02416518) | Sanford Health | 2014-05-01 |
| A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma (NCT02082977) | GlaxoSmithKline | 2014-04-24 |
| Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors. (NCT02106845) | Bayer | 2014-04-22 |
| My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (NCT02091141) | Genentech, Inc. | 2014-04-14 |
| A Study Of PF-06647263 In Patients With Advanced Solid Tumors (NCT02078752) | Pfizer | 2014-04-09 |
| Safety and Effectiveness of Regorafenib (NCT02042144) | Bayer | 2014-04-08 |
| A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors (NCT02092792) | Genentech, Inc. | 2014-04-01 |
| Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner (NCT02129335) | University Hospital, Basel, Switzerland | 2014-04-01 |
| Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) (NCT01964430) | Celgene | 2014-03-28 |
| Assessment of Cancer Pain in Emergency Department in Traditional Chinese Medicine (NCT02116218) | Changhua Christian Hospital | 2014-03-01 |
| Evaluating the Impact of Patient-Centered Oncology Care (NCT02110758) | National Committee for Quality Assurance | 2014-02-01 |
| Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty (NCT02082314) | Sunnybrook Health Sciences Centre | 2014-02-01 |
| Per-operating Use of a Probe for Detection of β+ (NCT02666599) | University of Lausanne Hospitals | 2014-02-01 |
| The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy (NCT02192216) | Department of Public Health, Denmark | 2014-02-01 |
| Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients (NCT01974258) | Hoffmann-La Roche | 2014-02-01 |
| Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator. (NCT02017860) | Novartis Pharmaceuticals | 2014-01-16 |
| A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy (NCT02111824) | The Methodist Hospital Research Institute | 2014-01-05 |
| MR Urography vs CT Urography (NCT02606513) | Kuopio University Hospital | 2014-01-01 |
| A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors (NCT02004106) | Hoffmann-La Roche | 2013-12-31 |
| Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib) (NCT01976741) | Bayer | 2013-12-30 |
| CORAL XT - Open-label Extension Trial of the CORAL Trial (NCT02031432) | Tris Pharma, Inc. | 2013-12-18 |
| Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours (NCT02020577) | Boehringer Ingelheim | 2013-12-01 |
| Evolution® Biliary Stent System Clinical Study (NCT01962168) | Cook Group Incorporated | 2013-12-01 |
| Relative Bioavailability of Pimasertib in Cancer Patients (NCT01992874) | EMD Serono | 2013-11-30 |
| A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body (NCT02014116) | Eli Lilly and Company | 2013-11-26 |
| Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors (NCT01966445) | GlaxoSmithKline | 2013-11-26 |
| Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (NCT01973868) | Bayer | 2013-11-21 |
| A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors (NCT01938443) | GlaxoSmithKline | 2013-11-18 |
| Advance Care Planning: A Way to Improve End-of-life Care Life Care (NCT01944813) | University of Aarhus | 2013-11-01 |
| Indocyanine Green for Solid Tumors (NCT02280954) | University of Pennsylvania | 2013-11-01 |
| Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors (NCT01968915) | Novartis Pharmaceuticals | 2013-11-01 |
| A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS (NCT01986166) | Genentech, Inc. | 2013-11-01 |
| Japanese Phase 1 Study of BMS-844203 (CT322) (NCT01146171) | Bristol-Myers Squibb | 2013-11-01 |
| CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer (NCT01964378) | Tris Pharma, Inc. | 2013-10-29 |
| Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known (NCT01971476) | Boehringer Ingelheim | 2013-10-22 |
| Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling (NCT01868022) | GlaxoSmithKline | 2013-10-09 |
| Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer (NCT01938638) | Bayer | 2013-09-26 |
| BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors (NCT01938846) | Boehringer Ingelheim | 2013-09-05 |
| A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors (NCT01911936) | Novartis Pharmaceuticals | 2013-09-01 |
| Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients (NCT01915576) | Bayer | 2013-09-01 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma (NCT01962532) | Janssen Research & Development, LLC | 2013-08-21 |
| A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants (NCT01767623) | Hoffmann-La Roche | 2013-08-20 |
| A Study Of PF-06263507 In Patients With Advanced Solid Tumors (NCT01891669) | Pfizer | 2013-08-08 |
| A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors (NCT01901172) | Hoffmann-La Roche | 2013-08-01 |
| A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (NCT01905111) | Boehringer Ingelheim | 2013-07-01 |
| First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors (NCT01881217) | Bayer | 2013-06-28 |
| Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial (NCT01995942) | Royal Marsden NHS Foundation Trust | 2013-06-07 |
| Preparing Family Caregivers to Make Medical Decisions for Their Loved Ones (NCT02429479) | Milton S. Hershey Medical Center | 2013-06-01 |
| Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2 (NCT01837693) | Azienda USL Reggio Emilia - IRCCS | 2013-06-01 |
| Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight (NCT01828554) | University of Wisconsin, Madison | 2013-06-01 |
| Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment (NCT01853046) | Bayer | 2013-06-01 |
| Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (NCT01789281) | Novartis Pharmaceuticals | 2013-05-14 |
| A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (NCT01815294) | Janssen Research & Development, LLC | 2013-05-01 |
| A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing (NCT01811095) | McGill University | 2013-03-01 |
| Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury (NCT01802996) | Cttq | 2013-03-01 |
| Cancer Experience Registry (CER) for Cancer Patients and Caregivers (NCT02333604) | Cancer Support Community, Research and Training Institute, Philadelphia | 2013-03-01 |
| A Study of ARGX-110 in Participants With Advanced Malignancies (NCT01813539) | OncoVerity, Inc. | 2013-02-27 |
| An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol (NCT01739764) | Hoffmann-La Roche | 2013-02-19 |
| BAY86-9766 Plus Gemcitabine Phase I Study in Asian (NCT01764828) | Bayer | 2013-02-05 |
| Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours (NCT01772563) | Boehringer Ingelheim | 2013-02-04 |
| Phase I Study of LB-100 With Docetaxel in Solid Tumors (NCT01837667) | Lixte Biotechnology Holdings, Inc. | 2013-02-01 |
| Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer (NCT01774409) | Centre Leon Berard | 2013-02-01 |
| Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients (NCT02891460) | UroGen Pharma Ltd. | 2013-01-01 |
| Impact of Physical Therapy Intervention on Foot and Ankle Function (NCT04930406) | Children's Hospitals and Clinics of Minnesota | 2012-12-18 |
| Open Label Study of BAY1082439 in Patients With Advanced Cancer (NCT01728311) | Bayer | 2012-11-21 |
| Study of LY2157299 in Japanese Participants With Cancer (NCT01722825) | Eli Lilly and Company | 2012-11-01 |
| A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors (NCT02025803) | Taiho Oncology, Inc. | 2012-11-01 |
| A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (NCT01684215) | Pfizer | 2012-10-19 |